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Abstract 
 
Objective 
Mutations in ABCC6 underlie the ectopic mineralization disorder pseudoxanthoma elasticum 
(PXE) and some forms of generalized arterial calcification of infancy (GACI), both of which 
affect the cardiovascular system. Using cultured cells, we recently showed that ABCC6 
mediates the cellular release of ATP, which is extracellularly rapidly converted into AMP and the 
mineralization inhibitor inorganic pyrophosphate (PPi). The current study was performed to 
determine which tissues release ATP in an ABCC6-dependent manner in vivo, where released 
ATP is converted into AMP and PPi, and whether human PXE patients have low plasma PPi 
concentrations. 
 
Approach and results 
Using cultured primary hepatocytes and in vivo liver perfusion experiments we found that 
ABCC6 mediates the direct, sinusoidal, release of ATP from the liver. Outside hepatocytes, but 
still within the liver vasculature, released ATP is converted into AMP and PPi. The absence of 
functional ABCC6 in PXE patients leads to strongly reduced plasma PPi concentrations. 
 
Conclusions 
Hepatic ABCC6-mediated ATP release is the main source of circulating PPi, revealing an 
unanticipated role of the liver in systemic PPi homeostasis. PXE patients have a strongly 
reduced plasma PPi level, explaining their mineralization disorder. Our results indicate that 
systemic PPi is relatively stable and that PXE, GACI and other ectopic mineralization disorders 
could be treated with PPi supplementation therapy. 
 
 
 
 
Non-standard Abbreviations and Acronyms 
 
ABCC6, ATP-binding cassette sub-family C member 6; 
ACDC, Arterial Calcification due to Deficiency of CD73; 
ANKH, progressive ankylosis protein homolog; 
ENPP, ectonucleotide pyrophosphatase-phosphodiesterase; 
GACI, General Arterial Calcification of Infancy; 
MRP6, Multidrug Resistance-associated Protein 6; 
NT5E, ecto-5’-nucleotidase; 
PPi, inorganic pyrophosphate; 
PXE, pseudoxanthoma elasticum 
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Introduction 
 
Pseudoxanthoma elasticum (PXE) is an autosomal recessive disease characterized by 
progressive ectopic mineralization of the skin, eyes and arteries1. Approximately 150,000 PXE 
patients world-wide suffer from stigmatizing skin lesions, progressive loss of vision and 
cardiovascular complications, against which no effective therapy exists2. 
In 2000, several groups reported that PXE is caused by inactivating mutations in the 
ATP-binding cassette sub-family C member 6 (ABCC6) gene3-5 and more recently ABCC6 
defects were also found to cause some forms of generalized arterial calcification of infancy 
(GACI)6, a severe form of arterial calcification. ABCC6 (also known as Multidrug Resistance 
Protein 6, MRP6) is an ATP-dependent orphan efflux transporter that is primarily expressed in 
the liver7. Importantly, PXE is not caused by a lack of ABCC6 in the affected tissues, but by the 
absence of an unknown factor in the central circulation requiring active ABCC68. Despite 
extensive research, the identity of this factor has long remained a mystery. 
We recently showed that overexpression of ABCC6 in HEK293 cells induces the release 
of nucleoside triphosphates, predominantly ATP, in vitro9. Secreted ATP was extracellularly 
converted into AMP and the mineralization inhibitor inorganic pyrophosphate (PPi) by 
ectonucleotide pyrophosphatase-phosphodiesterase (ENPP)-type ectonucleotidases. The in 
vivo relevance of these findings was demonstrated in Abcc6-/- mice, which have plasma PPi 
levels less than 40% of those found in wild-type control animals. ABCC6 is a member of the 
ABCC (MRP) family, which contains large proteins transporting a variety of organic anions10. 
ABCC6 is mainly present in the sinusoidal membrane of the hepatocytes11. As we could not 
demonstrate direct ABCC6-mediated ATP transport in vitro, we postulated that ABCC6 secretes 
an organic anion, factor X, into the circulation that induces local ATP release in the periphery9. 
The alternative possibility that the liver directly releases ATP in an ABCC6-dependent manner 
seemed unlikely. Secretion of ATP over the sinusoidal membrane of hepatocytes has never 
been described and the extremely short half-life of ATP in the blood circulation (<1 sec)12 does 
not allow PPi formation from liver-derived ATP in the periphery. The current study was 
performed to show that ABCC6 affects plasma PPi levels in humans and to assess whether 
ABCC6 directly affects hepatic ATP release or indirectly induces peripheral ATP release. 
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Materials and Methods 
 
Methods and Materials are available in the online-only Data Supplement. 
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Results 
 
We have previously shown that the introduction of ABCC6 in HEK293 cells results in the release 
of large amounts of ATP into the culture medium9. To determine whether ABCC6-dependent 
ATP release is cell type-dependent, we generated HeLa cells in which the expression of rat 
ABCC6 (rABCC6) could be induced by doxycycline. A luciferin/luciferase-based assay was used 
to follow the appearance of ATP in the cell culture medium in real-time. In the absence of 
rABCC6 cells released almost no ATP (Figure 1A and B). However, upon induction of rABCC6 
both 293 and HeLa cells released substantial amounts of ATP into the cell culture medium 
(Figure 1). These data show that ATP release is a general feature of ABCC6-containing cells 
and not specific for HEK293 cells. 
ABCC6 is predominantly present in the liver11. We therefore next explored in sandwich-
cultured hepatocytes the possibility that hepatocytes directly release ATP over their basolateral 
membrane in an ABCC6-dependent manner. We were unable to directly detect ATP release in 
these experiments, presumably due to the high ectonucleotidase activity of hepatocytes. We 
therefore followed the appearance of the ATP metabolite PPi in the culture medium. PPi levels 
clearly increased in culture medium of wild-type hepatocytes over time, with substantially lower 
levels detected in medium of hepatocytes lacking ABCC6 (Figure 2A). These results indicate 
that hepatocytes release ATP over their sinusoidal membrane in an ABCC6-dependent manner 
and are also able to convert it to PPi. We also detected some PPi in medium from Abcc6-/- cells, 
which we attribute to ATP release unrelated to ABCC6, or leakage from damaged cells. 
To assess whether ABCC6 is an important factor in hepatic ATP release in vivo, we 
performed liver perfusion experiments. PPi and AMP levels in the liver perfusates strongly 
depended on the presence of ABCC6 (Figure 2, panels B and C). Interestingly, ATP levels did 
not differ between the two genotypes and were extremely low, representing less than 1% of the 
PPi and AMP levels (Figure 1 D). The AMP and PPi that we detect in the liver perfusates must 
be derived from ATP: Enpp1-/- mice have PPi levels that are less than 5% of those found in wild-
type mice13, implying that also the PPi in plasma that depends on ABCC6 must come from ATP. 
Conversion of released ATP into AMP and PPi within the liver is fast. We calculated that during 
our single-pass perfusion experiments, the buffer is present in the liver for approximately 10 
seconds (for the calculation see the Materials and Methods section). During this short period the 
substantial amounts of ATP released are almost quantitatively converted into PPi and AMP 
(Figure 2B, C and D). This rapid and efficient conversion also explains why we were unable to 
detect ATP release from cultured wild-type hepatocytes: any released ATP is almost 
instantaneously converted into AMP and PPi by hepatic NPP1.  
From our perfusion experiments we calculate that ABCC6 mediates ~ 90% of the hepatic 
nucleotide release. Over 24 hours this corresponds to at least 5% of the total hepatic adenine 
nucleotide pool (Figure 2 B; for the calculation see the Materials and Methods section). The 
plasma t1/2 of PPi has been estimated to be 33 min, which requires a hepatic release rate of 6 
nmoles PPi per hour to achieve the steady-state levels of 2.3 µmol/L (µM) that we have reported 
for mice9 (for calculation see the Materials and Methods section). Importantly, the amount of PPi 
detected in liver perfusates of wild-type mice is high enough to explain these steady-state PPi 
levels in mouse plasma. 
An important question is whether our mouse results translate to human PXE patients. 
We have therefore studied a group of 12 Dutch PXE patients with known ABCC6 mutations 
(Materials and Methods Table 1). The plasma PPi concentrations were approximately 2.5-fold 
lower in patients than in healthy individuals (Figure 2 E). This difference did not depend on sex 
and is in line with the reduced plasma PPi levels we previously reported for Abcc6-/- mice9.  
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Discussion 
PPi is a key regulator of ectopic mineralization acting by inhibiting hydroxyapatite crystal 
growth14. As a result, mutations in genes encoding known PPi-regulating enzymes like ENPP1, 
ecto-5’-nucleotidase (NT5E), progressive ankylosis protein homolog (ANKH) and tissue-
nonspecific alkaline phosphatase (TNAP) cause various mineralization disorders15-18. The 
clinical symptoms of the mineralization disorders caused by non-functional ENPP1 (generalized 
arterial calcification of infancy; GACI) and NT5E (arterial calcification due to deficiency of CD73; 
ACDC) highly overlap those of PXE19. The similarity between GACI and PXE is underlined by 
the recent observations that both GACI and PXE can be caused by mutations in ENPP1 as well 
as ABCC66. Our data unexpectedly falsify the factor X-hypothesis9 and show that ABCC6-
mediated ATP release from the liver is the principal source of plasma PPi. A factor involved in 
the local release of PPi is ANKH, a membrane protein postulated to mediate the direct release 
of PPi from cells. ANKH does, however, not substantially contribute to plasma PPi levels, which 
almost exclusively depend on ENPP1 activity and hence ATP release13. Based on the currently 
available data we propose the model presented in Figure 3. 
Our finding that PPi generated within the liver is able to act in the periphery shows that 
increased systemic PPi levels are sufficient to inhibit local ectopic mineralization. Importantly, 
Lomashvili et al. very recently showed in Enpp1-/- mice that ectopic calcification indeed depends 
on plasma PPi levels and not local PPi production13. The crucial role of plasma PPi in the 
prevention of ectopic calcification has important therapeutic consequences: Raising PPi levels in 
the blood circulation of PXE, GACI and ACDC patients should suffice to halt ectopic 
mineralization. The short plasma half-life and lack of a suitable dosage form do not make PPi an 
attractive candidate for supplementation therapy in humans20, but it might be possible to 
generate suitable PPi precursors. Alternatively, bisphosphonates, a class of metabolically 
stable, synthetic PPi analogs that have been used in GACI with reasonable success21, may 
represent an attractive treatment strategy for PXE and ACDC. 
The AMP metabolite adenosine is known to inhibit the expression of TNAP (Figure 2)16. 
It is therefore tempting to speculate that the increased TNAP activity seen in fibroblasts isolated 
from PXE patients22 and Abcc6-/- mice23 is due to a reduction in the amount of released AMP. 
Low AMP levels might reduce local formation of adenosine and subsequent TNAP inhibition. 
AMP-derived adenosine might, therefore, be involved in “priming” of the periphery for 
subsequent PPi influx. This model would imply that both AMP and PPi, are necessary to prevent 
ectopic mineralization: PPi by directly inhibiting the formation of calcium phosphate crystals and 
AMP after being metabolized to adenosine by inhibiting premature degradation of circulating PPi 
by TNAP. 
In vitro, ABCC6 transports glutathione conjugates and the synthetic cyclic peptide BQ-
123, suggesting that ABCC6 is a bona-fide transporter11, 24. We were unable, however, to 
demonstrate ABCC6-mediated nucleoside triphosphate transport in vesicular transport 
experiments9. Factors could be missing in vitro, however, that allow ABCC6 to transport ATP in 
vivo, or ABCC6 could indirectly stimulate ATP release by regulating vesicular transport or ion-
channels25.  
Taken together, we show that ABCC6 mediates the release of ATP directly from the liver 
into the circulation. Within the liver vasculature, ATP is converted into AMP and PPi and 
represents the main source of the mineralization inhibitor PPi in plasma. This fully explains why 
absence of ABCC6 results in the ectopic mineralization observed in PXE patients. Our data 
indicate that correcting PPi to normal levels could prevent the ectopic mineralization observed in 
PXE, GACI and ACDC. 
 7
Acknowledgements 
 
 
Acknowledgements 
We thank our colleague Alfred Schinkel for critically reading the manuscript. Pyruvate 
orthophosphate dikinase was kindly provided by Kikkoman Biochemifa, Tokyo, Japan. 
 
Sources of funding 
Our work is supported by PXE international and a Hungarian Research Foundation Grant 
(OTKA-104227). 
  
Disclosures 
The authors declare that they have no conflict of interest. 
 8
References 
 
1. Neldner KH. Pseudoxanthoma elasticum. Clin. Dermatol. 1988;6:1-159 
2. Uitto J, Varadi A, Bercovitch L, Terry PF, Terry SF. Pseudoxanthoma elasticum: 
Progress in research toward treatment: Summary of the 2012 pxe international research 
meeting. J. Invest. Dermatol. 2013;133:1444-1449 
3. Le Saux O, Urban Z, Tschuch C, Csiszar K, Bacchelli B, Quaglino D, Pasquali-Ronchetti 
I, Pope FM, Richards A, Terry S, Bercovitch L, de Paepe A, Boyd CD. Mutations in a 
gene encoding an abc transporter cause pseudoxanthoma elasticum. Nat. Genet. 
2000;25:223-227 
4. Bergen AA, Plomp AS, Schuurman EJ, Terry S, Breuning M, Dauwerse H, Swart J, Kool 
M, van Soest S, Baas F, ten Brink JB, de Jong PT. Mutations in abcc6 cause 
pseudoxanthoma elasticum. Nat. Genet. 2000;25:228-231 
5. Ringpfeil F, Lebwohl MG, Christiano AM, Uitto J. Pseudoxanthoma elasticum: Mutations 
in the mrp6 gene encoding a transmembrane atp-binding cassette (abc) transporter. 
Proc. Natl. Acad. Sci. U. S. A. 2000;97:6001-6006 
6. Nitschke Y, Rutsch F. Generalized arterial calcification of infancy and pseudoxanthoma 
elasticum: Two sides of the same coin. Front. Genet. 2012;3:302 
7. Kool M, van der Linden M, de Haas M, Baas F, Borst P. Expression of human mrp6, a 
homologue of the multidrug resistance protein gene mrp1, in tissues and cancer cells. 
Cancer Res. 1999;59:175-182 
8. Jiang Q, Oldenburg R, Otsuru S, Grand-Pierre AE, Horwitz EM, Uitto J. Parabiotic 
heterogenetic pairing of abcc6-/-/rag1-/- mice and their wild-type counterparts halts 
ectopic mineralization in a murine model of pseudoxanthoma elasticum. Am. J. Pathol. 
2010;176:1855-1862 
9. Jansen R, Küçükosmanoğlu A, de Haas M, Sapthu S, Otero J, Hegman I, Bergen A, 
Gorgels T, Borst P, van de Wetering K. Abcc6 prevents ectopic mineralization seen in 
pseudoxanthoma elasticum by inducing cellular nucleotide release. Proc. Natl. Acad. 
Sci. 2013 
10. Borst P, Oude Elferink RP. Mammalian abc transporters in health and disease. Annu. 
Rev. Biochem. 2002;71:537-592 
11. Madon J, Hagenbuch B, Landmann L, Meier PJ, Stieger B. Transport function and 
hepatocellular localization of mrp6 in rat liver. Mol Pharmacol. 2000;57:634-641 
12. Mortensen SP, Thaning P, Nyberg M, Saltin B, Hellsten Y. Local release of atp into the 
arterial inflow and venous drainage of human skeletal muscle: Insight from atp 
determination with the intravascular microdialysis technique. J. Physiol. 2011;589:1847-
1857 
13. Lomashvili KA, Narisawa S, Millan JL, O'Neill WC. Vascular calcification is dependent on 
plasma levels of pyrophosphate. Kidney Int. 2014 
14. Fleisch H, Russell RG, Straumann F. Effect of pyrophosphate on hydroxyapatite and its 
implications in calcium homeostasis. Nature. 1966;212:901-903 
15. Rutsch F, Ruf N, Vaingankar S, Toliat MR, Suk A, Hohne W, Schauer G, Lehmann M, 
Roscioli T, Schnabel D, Epplen JT, Knisely A, Superti-Furga A, McGill J, Filippone M, 
Sinaiko AR, Vallance H, Hinrichs B, Smith W, Ferre M, Terkeltaub R, Nurnberg P. 
Mutations in enpp1 are associated with 'idiopathic' infantile arterial calcification. Nat. 
Genet. 2003;34:379-381 
16. St Hilaire C, Ziegler SG, Markello TC, Brusco A, Groden C, Gill F, Carlson-Donohoe H, 
Lederman RJ, Chen MY, Yang D, Siegenthaler MP, Arduino C, Mancini C, Freudenthal 
B, Stanescu HC, Zdebik AA, Chaganti RK, Nussbaum RL, Kleta R, Gahl WA, Boehm M. 
Nt5e mutations and arterial calcifications. N. Engl. J. Med. 2011;364:432-442 
 9
17. Henthorn PS, Raducha M, Fedde KN, Lafferty MA, Whyte MP. Different missense 
mutations at the tissue-nonspecific alkaline phosphatase gene locus in autosomal 
recessively inherited forms of mild and severe hypophosphatasia. Proc. Natl. Acad. Sci. 
U. S. A. 1992;89:9924-9928 
18. Pendleton A, Johnson MD, Hughes A, Gurley KA, Ho AM, Doherty M, Dixey J, Gillet P, 
Loeuille D, McGrath R, Reginato A, Shiang R, Wright G, Netter P, Williams C, Kingsley 
DM. Mutations in ankh cause chondrocalcinosis. Am. J. Hum. Genet. 2002;71:933-940 
19. Rutsch F, Nitschke Y, Terkeltaub R. Genetics in arterial calcification: Pieces of a puzzle 
and cogs in a wheel. Circ. Res. 2011;109:578-592 
20. O'Neill WC, Lomashvili KA, Malluche HH, Faugere MC, Riser BL. Treatment with 
pyrophosphate inhibits uremic vascular calcification. Kidney Int. 2011;79:512-517 
21. Rutsch F, Boyer P, Nitschke Y, Ruf N, Lorenz-Depierieux B, Wittkampf T, Weissen-
Plenz G, Fischer RJ, Mughal Z, Gregory JW, Davies JH, Loirat C, Strom TM, Schnabel 
D, Nurnberg P, Terkeltaub R. Hypophosphatemia, hyperphosphaturia, and 
bisphosphonate treatment are associated with survival beyond infancy in generalized 
arterial calcification of infancy. Circ. Cardiovasc. Genet. 2008;1:133-140 
22. Boraldi F, Annovi G, Bartolomeo A, Quaglino D. Fibroblasts from patients affected by 
pseudoxanthoma elasticum exhibit an altered ppi metabolism and are more responsive 
to pro-calcifying stimuli. J. Dermatol. Sci. 2014 
23. Boraldi F, Bartolomeo A, Li Q, Uitto J, Quaglino D. Changes in dermal fibroblasts from 
abcc6-/- mice are present before and after the onset of ectopic tissue mineralization. J. 
Invest. Dermatol. 2014 
24. Ilias A, Urban Z, Seidl TL, Le Saux O, Sinko E, Boyd CD, Sarkadi B, Varadi A. Loss of 
atp-dependent transport activity in pseudoxanthoma elasticum-associated mutants of 
human abcc6 (mrp6). J. Biol. Chem. 2002;277:16860-16867 
25. Lazarowski ER. Vesicular and conductive mechanisms of nucleotide release. Purinergic 
Signal. 2012;8:359-373 
 10
Significance 
PXE is a hereditary ectopic mineralization disorder caused by the absence of functional ABCC6 
that affects approximately 150,000 patients world-wide. An effective therapy does not exist as 
the pathology underlying the disease is not well understood. Here we show that ABCC6-
mediated ATP secretion by the liver is the main source of the mineralization inhibitor inorganic 
pyrophosphate in the systemic circulation, explaining the ectopic calcification observed in PXE 
patients. Our data indicate that correcting PPi to normal levels could prevent the ectopic 
mineralization observed in PXE and related mineralization disorders. 
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